Oritavancin shortens treatment time for complicated skin-structure infections

March 1, 2002

Chicago - Oritavancin (InterMune), an investigational glycopeptidewith activity against a wide range of Gram-positive pathogens, has beenshown to cut the treatment time in half for complicated skin and skin structureinfections (CSSIs) compared to current standard therapy with vancomycinplus cephalexin, Margaret Wasilewski, M.D., said at the 41st InterscienceConference on Antimicrobial Agents & Chemotherapy.

Related Content:

News